COMPASS Pathways (NASDAQ:CMPS) Stock Price Up 4.6%

COMPASS Pathways plc (NASDAQ:CMPS) shares traded up 4.6% on Tuesday . The company traded as high as $8.73 and last traded at $8.70. 317,074 shares were traded during mid-day trading, a decline of 55% from the average session volume of 701,797 shares. The stock had previously closed at $8.32.

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. Morgan Stanley started coverage on shares of COMPASS Pathways in a research note on Monday, April 1st. They issued an “overweight” rating and a $30.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and set a $120.00 price target on shares of COMPASS Pathways in a research report on Friday, March 1st. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of “Buy” and a consensus target price of $47.40.

COMPASS Pathways Trading Up 2.0 %

The company has a market cap of $538.88 million, a PE ratio of -3.57 and a beta of 2.48. The company has a quick ratio of 13.33, a current ratio of 13.33 and a debt-to-equity ratio of 0.14. The business has a 50-day simple moving average of $10.03 and a 200-day simple moving average of $8.34.

COMPASS Pathways (NASDAQ:CMPS) last announced its earnings results on Thursday, February 29th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.16). On average, analysts predict that COMPASS Pathways plc will post -2.4 EPS for the current fiscal year.

Insiders Place Their Bets

In other COMPASS Pathways news, major shareholder George Jay Goldsmith sold 25,750 shares of the business’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $8.96, for a total value of $230,720.00. Following the completion of the transaction, the insider now owns 4,010,404 shares in the company, valued at $35,933,219.84. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, major shareholder George Jay Goldsmith sold 25,750 shares of the business’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $8.96, for a total value of $230,720.00. Following the completion of the sale, the insider now directly owns 4,010,404 shares of the company’s stock, valued at $35,933,219.84. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Ekaterina Malievskaia sold 19,853 shares of the business’s stock in a transaction on Tuesday, February 6th. The shares were sold at an average price of $10.59, for a total transaction of $210,243.27. Following the completion of the sale, the director now directly owns 4,144,994 shares of the company’s stock, valued at $43,895,486.46. The disclosure for this sale can be found here. Insiders sold a total of 162,675 shares of company stock worth $1,511,656 over the last 90 days. Corporate insiders own 23.99% of the company’s stock.

Institutional Investors Weigh In On COMPASS Pathways

Institutional investors and hedge funds have recently bought and sold shares of the stock. Goldman Sachs Group Inc. raised its holdings in shares of COMPASS Pathways by 122.9% in the fourth quarter. Goldman Sachs Group Inc. now owns 53,587 shares of the company’s stock valued at $469,000 after buying an additional 29,550 shares during the last quarter. Empire Financial Management Company LLC purchased a new position in COMPASS Pathways during the fourth quarter worth about $271,000. Barclays PLC grew its position in COMPASS Pathways by 21.4% during the fourth quarter. Barclays PLC now owns 501,310 shares of the company’s stock worth $4,387,000 after buying an additional 88,244 shares during the period. PFM Health Sciences LP grew its position in COMPASS Pathways by 540.7% during the fourth quarter. PFM Health Sciences LP now owns 338,761 shares of the company’s stock worth $2,964,000 after buying an additional 285,890 shares during the period. Finally, Gilder Gagnon Howe & Co. LLC acquired a new position in COMPASS Pathways during the fourth quarter worth about $265,000. 46.19% of the stock is owned by hedge funds and other institutional investors.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.